The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, driving up Depomed Inc.'s stock value by 11 percent. (BioWorld Today)

The FDA issued an approvable letter for Glumetza, a once-daily, extended-release version of the diabetes drug metformin, driving up Depomed Inc.'s stock value by 11 percent. (BioWorld Today)